Literature DB >> 25323325

Glucagon for hypoglycemic episodes in insulin-treated diabetic patients: a systematic review and meta-analysis with a comparison of glucagon with dextrose and of different glucagon formulations.

Augusto Boido1, Valerio Ceriani, Antonio E Pontiroli.   

Abstract

AIMS: Glucagon is used as an emergency drug in hypoglycemia, mainly when the patient is unconscious. A few studies report on ineffectiveness of glucagon in relieving hypoglycemia. The present systematic review and meta-analysis evaluate the effectiveness of glucagon alone and in comparison with dextrose and the effectiveness of intranasal glucagon in comparison with injected glucagon.
METHODS: Studies were grouped into three groups: (1) reports on glucagon ineffectiveness; (2) comparison of glucagon and dextrose; (3) comparison of intranasal glucagon and injected glucagon. In groups 2 and 3, only controlled studies were included in the analysis, whether randomized or non-randomized studies. Appropriate methodology (PRISMA statement) was adhered to, and publication bias was formally assessed. Sixteen studies, published in any language as full papers, were analysed to identify predictors of ineffectiveness, and they were included in a meta-analysis (random effects model) to study the effect of different strategies. Intervention effect (number of failures) was expressed as odds ratio (OR), with 95 % confidence intervals.
RESULTS: Failure rate ranged from 0.0 to 2.31 %, to 7.6 %, to 14.4 %, and to 59 %. Comparing glucagon and dextrose, the OR was 0.53 (0.20-1.42); comparing intranasal and intramuscular glucagon, the OR was 1.40 (0.18-10.93). Heterogeneity was low and not statistically significant. Publication bias was absent.
CONCLUSIONS: These data indicate that ineffectiveness of glucagon is unfrequent, not different from dextrose; in addition, intranasal and injected glucagon are similarly effective. In the case of failure, a second dose can be administered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25323325     DOI: 10.1007/s00592-014-0665-0

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  7 in total

1.  Nasal Glucagon Versus Injectable Glucagon for Severe Hypoglycemia: A Cost-Offset and Budget Impact Analysis.

Authors:  Johannes Pöhlmann; Beth D Mitchell; Sanjay Bajpai; Beatrice Osumili; William J Valentine
Journal:  J Diabetes Sci Technol       Date:  2019-01-30

2.  Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis.

Authors:  Antonio E Pontiroli; Elena Tagliabue
Journal:  Acta Diabetol       Date:  2020-02-06       Impact factor: 4.280

3.  Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study.

Authors:  Jean-François Yale; Hélène Dulude; Marc Egeth; Claude A Piché; Martin Lafontaine; Dolorès Carballo; Rebecca Margolies; Emily Dissinger; Adam R Shames; Nicole Kaplowitz; Michelle Xiaotian Zhang; Shuyu Zhang; Cristina B Guzman
Journal:  Diabetes Technol Ther       Date:  2017-05-30       Impact factor: 6.118

Review 4.  New uses and formulations of glucagon for hypoglycaemia.

Authors:  Pilar I Beato-Víbora; Francisco J Arroyo-Díez
Journal:  Drugs Context       Date:  2019-07-30

5.  Usability of Nasal Glucagon Device: Partially Randomized Caregiver and Third-Party User Experience Trial with Simulated Administration at a Japanese Site.

Authors:  Toshihiko Aranishi; Yukiko Nagai; Yasushi Takita; Shuyu Zhang; Rimei Nishimura
Journal:  Diabetes Ther       Date:  2019-11-04       Impact factor: 2.945

6.  Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes.

Authors:  Jennifer L Sherr; Katrina J Ruedy; Nicole C Foster; Claude A Piché; Hélène Dulude; Michael R Rickels; William V Tamborlane; Kathleen E Bethin; Linda A DiMeglio; Larry A Fox; R Paul Wadwa; Desmond A Schatz; Brandon M Nathan; Santica M Marcovina; Emmanouil Rampakakis; Linyan Meng; Roy W Beck
Journal:  Diabetes Care       Date:  2016-02-16       Impact factor: 19.112

7.  Intraperitoneal, subcutaneous and intravenous glucagon delivery and subsequent glucose response in rats: a randomized controlled crossover trial.

Authors:  Ilze Dirnena-Fusini; Marte Kierulf Åm; Anders Lyngvi Fougner; Sven Magnus Carlsen; Sverre Christian Christiansen
Journal:  BMJ Open Diabetes Res Care       Date:  2018-11-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.